Compare · CVET vs MCK
CVET vs MCK
Side-by-side comparison of Covetrus Inc. (CVET) and McKesson Corporation (MCK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CVET and MCK operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- MCK is the larger of the two at $92.15B, about 38.0x CVET ($2.42B).
- MCK has hit the wire 35 times in the past 4 weeks while CVET has been quiet.
- MCK has more recent analyst coverage (25 ratings vs 8 for CVET).
- Company
- Covetrus Inc.
- McKesson Corporation
- Price
- $21.00+0.24%
- $766.63-1.18%
- Market cap
- $2.42B
- $92.15B
- 1M return
- -
- +1.61%
- 1Y return
- -
- +8.34%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 35
- Recent ratings
- 8
- 25
Covetrus Inc.
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions that include, inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.
McKesson Corporation
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Latest CVET
- Semrush Strengthens Customer Focus with Appointment of Veronique Montreuil as Chief Customer and Data Officer
- Key Cannabis Exec Changes You Need To Know About: Leafly's New CCO, Glass House's New Appointment & More
- SEC Form 15-12G filed by Covetrus Inc.
- Westlake Set to Join S&P MidCap 400; MillerKnoll to Join S&P SmallCap 600
- Westlake Set To Join S&P MidCap 400, Replacing MillerKnoll; MillerKnoll To Replace Coventrus In S&P SmallCap 600
- SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)
- SEC Form 4: Cd&R Investment Associates Ix, Ltd. disposed of 33,670,541 shares
- SEC Form S-8 POS filed by Covetrus Inc.
- SEC Form SC 13E3/A filed by Covetrus Inc. (Amendment)
- Covetrus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Latest MCK
- SVP, Controller & CAO Rutledge Napoleon B Jr sold $101,612 worth of shares (133 units at $764.00) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 632 units (SEC Form 4)
- EVP, Chief Strategy & BDO Rodgers Thomas L sold $604,420 worth of shares (822 units at $735.30) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 2,268 units (SEC Form 4)
- EVP & Chief HR Officer Smith Leann B sold $1,331,255 worth of shares (1,810 units at $735.50) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 4,798 units (SEC Form 4)
- McKesson Closes Strategic Investment with Apollo Funds for Minority Interest in Medical-Surgical Solutions
- SEC Form 4 filed by EVP & CFO Cheung Kenny K
- SEC Form 3 filed by new insider Cheung Kenny K
- SEC Form SD filed by McKesson Corporation
- EVP and Chief Legal Officer Lau Michele sold $2,701,870 worth of shares (3,550 units at $761.09) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 3,247 units (SEC Form 4)
- EVP & CFO Vitalone Britt J. converted options into 1,476 shares and covered exercise/tax liability with 581 shares, increasing direct ownership by 4% to 21,953 units (SEC Form 4)
- Chief Executive Officer Tyler Brian S. converted options into 4,579 shares and covered exercise/tax liability with 1,831 shares, increasing direct ownership by 11% to 27,774 units (SEC Form 4)